Johnson & Johnson (JNJ) Shares Bought by Peoples Bank OH

Peoples Bank OH lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 5.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 9,335 shares of the company’s stock after purchasing an additional 493 shares during the quarter. Johnson & Johnson comprises approximately 0.7% of Peoples Bank OH’s investment portfolio, making the stock its 23rd biggest position. Peoples Bank OH’s holdings in Johnson & Johnson were worth $1,133,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Financial Gravity Wealth Inc. acquired a new position in Johnson & Johnson during the 1st quarter worth about $105,000. FNY Investment Advisers LLC acquired a new position in Johnson & Johnson during the 2nd quarter worth about $117,000. Princeton Capital Management LLC acquired a new position in Johnson & Johnson during the 1st quarter worth about $141,000. Live Your Vision LLC lifted its stake in Johnson & Johnson by 58.3% during the 2nd quarter. Live Your Vision LLC now owns 1,363 shares of the company’s stock worth $172,000 after acquiring an additional 502 shares in the last quarter. Finally, Signition LP acquired a new position in Johnson & Johnson during the 1st quarter worth about $204,000. Institutional investors and hedge funds own 66.70% of the company’s stock.

JNJ stock opened at $137.55 on Tuesday. The company has a current ratio of 1.65, a quick ratio of 1.33 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $367.48 billion, a price-to-earnings ratio of 18.84, a P/E/G ratio of 2.14 and a beta of 0.70. Johnson & Johnson has a 1 year low of $118.62 and a 1 year high of $148.32.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 16th. The company reported $2.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.03 by $0.02. The company had revenue of $20.35 billion for the quarter, compared to analyst estimates of $20.05 billion. Johnson & Johnson had a return on equity of 34.97% and a net margin of 1.89%. Johnson & Johnson’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same quarter last year, the company earned $1.90 EPS. Equities analysts forecast that Johnson & Johnson will post 8.16 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 11th. Shareholders of record on Tuesday, November 27th will be given a $0.90 dividend. This represents a $3.60 dividend on an annualized basis and a yield of 2.62%. The ex-dividend date of this dividend is Monday, November 26th. Johnson & Johnson’s dividend payout ratio is currently 49.32%.

JNJ has been the topic of several research reports. Raymond James increased their target price on Johnson & Johnson from $144.00 to $149.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 17th. Credit Suisse Group increased their target price on Johnson & Johnson from $149.00 to $152.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 17th. Goldman Sachs Group raised Johnson & Johnson from a “sell” rating to a “neutral” rating in a research note on Thursday, July 12th. Citigroup increased their target price on Johnson & Johnson from $137.00 to $148.00 and gave the stock a “neutral” rating in a research note on Monday, October 22nd. Finally, ValuEngine raised Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Saturday, July 28th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $142.54.

In other Johnson & Johnson news, COO Michael E. Sneed sold 29,000 shares of the stock in a transaction dated Monday, August 27th. The stock was sold at an average price of $134.80, for a total value of $3,909,200.00. Following the sale, the chief operating officer now owns 59,124 shares of the company’s stock, valued at approximately $7,969,915.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Ronald A. Kapusta sold 7,899 shares of the stock in a transaction dated Friday, September 7th. The shares were sold at an average price of $137.18, for a total value of $1,083,584.82. Following the completion of the sale, the chief accounting officer now directly owns 25,725 shares in the company, valued at approximately $3,528,955.50. The disclosure for this sale can be found here. 0.22% of the stock is owned by company insiders.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: What kind of dividend yield to CEF’s pay?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply